drugset / Trial / NCT06563596
Epco, Zanu, Ritux for R/R FL or MZL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)
Timeline
- Start
- 2025-01-21
- Primary completion
- 2028-03-01
- Completion
- 2030-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |
| Subject | Zanubrutinib | Small molecule | 80 mg | Oral |